Trial · NCT02829320
Outcomes22
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 20 of 22
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Change From Baseline in Hgb at Week 4 | Baseline and Week 4 | All Treated Subjects Population | G/dL | MEAN |
| PRIMARY | Number of Participants by Hgb Change From Baseline Category at Week 4 | Baseline and Week 4 | All Treated Subjects Population | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Hgb Values at the Indicated Time Points | Up to Week 24 | All Treated Subjects Population | G/dL | MEAN |
| SECONDARY | Change From Baseline in Hgb at the Indicated Time Points | Baseline and up to Week 24 | All Treated Subjects Population | G/dL | MEAN |
| SECONDARY | Number of Participants Who Had Hgb Level Within the Target Range (10.0-12.0 g/dL) | Up to Week 24 | All Treated Subjects Population | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Time to Reach the Lower Target Hgb Level (10.0 g/dL) | Up to Week 24 | All Treated Subjects Population | Days | MEDIAN |
| SECONDARY | Number of Participants Who Had Hgb Level of Less Than 7.5 g/dL | Up to Week 24 | All Treated Subjects Population | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Number of Participants Who Had Hgb Increase of More Than 2 g/dL Over Any 4 Weeks | Up to Week 24 | All Treated Subjects Population | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Number of Participants Who Had Hgb Level of More Than 13.0 g/dL | Up to Week 24 | All Treated Subjects Population | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Number of Episodes of Achieving Hgb Level of More Than 13.0 g/dL | Up to Week 24 | All Treated Subjects Population | Episodes | NUMBER |
| SECONDARY | Area Under the Concentration-time Curve (AUC) From Time Zero to 4 Hours (AUC [0-4]) of GSK1278863 | 1, 2, 3 and 4 hours post dose at Weeks 12 and 24 | PK Population | Hour*nanogram per milliliter (h*ng/mL) | GEOMETRIC_MEAN |
| SECONDARY | Maximum Observed Concentration (Cmax) of GSK1278863 | 1, 2, 3 and 4 hours post dose at Weeks 12 and 24 | PK Population | ng/mL | GEOMETRIC_MEAN |
| SECONDARY | Monthly Average Dose of Intravenous (IV) Iron During the Treatment Period | Up to Week 24 | All Treated Subjects Population | Mg | MEAN |
| SECONDARY | Number of Participants Who Used Iron During the Treatment Period | Up to Week 24 | All Treated Subjects Population | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Change From Baseline in Ferritin | Baseline and up to Week 24 | All Treated Subjects Population | Microgram per liter (µg/L) | MEAN |
| SECONDARY | Percent Change From Baseline in TSAT | Baseline and up to Week 24 | All Treated Subjects Population | Percentage of transferrin | GEOMETRIC_MEAN |
| SECONDARY | Percent Change From Baseline in Hepcidin | Baseline and up to Week 24 | All Treated Subjects Population | Percentage of hepcidin | GEOMETRIC_MEAN |
| SECONDARY | Change From Baseline in Serum Iron | Baseline and up to Week 24 | All Treated Subjects Population | Micromoles per liter (µmol/L) | MEAN |
| SECONDARY | Change From Baseline in Total Iron Binding Capacity (TIBC) | Baseline and up to Week 24 | All Treated Subjects Population | umol/L | MEAN |
| SECONDARY | Dose Level of GSK1278863 at Indicated Time Points | Up to Week 24 | All Treated Subjects Population | mg | MEDIAN |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02829320/outcomes